![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
How Effective is Venetoclax Retreatment?
How Effective is Retreatment with Venetoclax?
If your first treatment was venetoclax in combination with a monoclonal antibody, you may wonder if venetoclax can be used again to treat your CLL.
In a 2022 study, researchers explored the outcomes of retreating CLL patients with venetoclax. The data below is a combination of patients treated with venetoclax plus a monoclonal antibody (obinutuzumab/rituximab) or venetoclax alone.
| Response Type | Efficacy |
| Average time in remission (progression-free survival) after retreatment | 2.1 years |
| The percentage of CLL patients who achieve undetectable minimal residual disease (uMRD) after finishing retreatment | 41.7% |
| Percentage of patients that experienced a complete response (full reduction of CLL signs/symptoms) after retreatment | 33.3% |
| Percentage of patients that experienced a partial response (partial reduction of CLL signs/symptoms) after retreatment | 46.2% |
| Percentage of CLL patients who experienced stable disease (CLL remained the same despite retreatment) | 18.0% |
| Progressive disease (CLL advanced despite retreatment) | 2.6% |
Retreatment with venetoclax shows a lower rate of response and shorter time in remission than what is seen when venetoclax is used as a first-time treatment and in earlier lines of therapy.
If your CLL comes back less than a year after your first venetoclax treatment, CLL specialists recommend other treatments, such as a BTK inhibitor, rather than being treated again with the same therapy.
Financial Resources for Venetoclax
Click here to locate financial resources for venetoclax. For additional resources, click here to visit the financial support section of the guide.